Phathom Pharmaceuticals (PHAT) Total Current Liabilities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Total Current Liabilities data on file, last reported at $125.0 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $125.0 million, up 68.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $125.0 million (up 68.9% YoY), and the FY2025 annual result was $132.0 million, up 54.03% from the prior year.
• Total Current Liabilities slipped to $125.0 million in Q1 2026 per PHAT's latest filing, from $132.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $132.0 million in Q4 2025 and troughed at $11.4 million in Q1 2022.
• A 5-year average of $55.2 million and a median of $43.5 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities plunged 72.1% in 2022, then surged 200.9% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $26.2 million in 2022, then soared by 47.81% to $38.8 million in 2023, then soared by 121.06% to $85.7 million in 2024, then surged by 54.03% to $132.0 million in 2025, then slipped by 5.3% to $125.0 million in 2026.
• Business Quant data shows PHAT's Total Current Liabilities at $125.0 million in Q1 2026, $132.0 million in Q4 2025, and $93.1 million in Q3 2025.